Loading...
Loading...
XOMA| Name | Value |
|---|---|
| Revenues | 1,658.0K |
| Cost of Revenue | 224.0K |
| Gross Profit | 1,434.0K |
| Operating Expense | 6,040.0K |
| Operating I/L | -5,957.0K |
| Other Income/Expense | 557.0K |
| Interest Income | 472.0K |
| Pretax | -5,400.0K |
| Income Tax Expense | 1,018.0K |
| Net Income/Loss | -5,400.0K |
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring the potential future economics associated with pre-commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets, and it helps biotech companies enhance human health by providing financial support in exchange for future royalties from successful products.
